EOM Attribution Errors in Cancer Care Raise Concerns Over Value-Based Care Accuracy

McKesson and The US Oncology Network have identified significant issues with Episode of Care (EOM) attribution in cancer treatment, particularly for oral therapies, according to a report published by HealthData.org. The findings highlight a growing risk to the accuracy and accountability of value-based care models, which rely on precise data to assess treatment effectiveness and financial outcomes.

What Are EOM Attribution Errors, and Why Do They Matter?

EOM attribution is a method used to categorize and track patient care episodes, ensuring that treatments like chemotherapy or targeted therapies are properly documented for billing and quality metrics. However, researchers found that oral cancer therapies—such as pills or liquid formulations—are frequently mislabeled or undercounted in EOM systems. This discrepancy can lead to incomplete data on treatment efficacy, financial underreporting for providers, and potential gaps in patient care coordination.

“Oral therapies are often administered outside traditional office settings, making them harder to track,” said Dr. Sarah Lin, a health policy analyst at the National Institutes of Health (NIH). “If these episodes aren’t accurately recorded, it undermines the entire value-based care framework, which depends on transparency.”

How Do These Errors Affect Value-Based Care Models?

Value-based care shifts reimbursement from volume to quality, rewarding providers for effective, cost-efficient care. Misattributed EOM data could misrepresent a provider’s performance, leading to unfair penalties or missed incentives. For example, if a patient’s oral therapy is incorrectly classified as a routine follow-up, the provider might not receive credit for managing a complex condition, despite the clinical effort involved.

A 2023 study in the Journal of the American Medical Association (JAMA) found that 18% of oral cancer treatments in outpatient settings were misclassified in EOM systems, with disparities noted in rural and safety-net hospitals. “This isn’t just a technical glitch—it’s a systemic issue that could widen inequities in care,” said the study’s lead author, Dr. Michael Torres.

What Are Stakeholders Doing to Address the Problem?

McKesson and The US Oncology Network have partnered with the Centers for Medicare & Medicaid Services (CMS) to pilot improved EOM tracking tools. These include enhanced electronic health record (EHR) templates and standardized coding for oral therapies. “We’re working to ensure that every episode of care—whether in a clinic, at home, or in a pharmacy—is accurately captured,” said a McKesson spokesperson in a statement.

CMS has also proposed new guidelines for EOM reporting, emphasizing the need for real-time data integration. However, some providers argue that implementing these changes requires significant infrastructure investments. “Small practices, in particular, lack the resources to adapt quickly,” noted the American Medical Association (AMA) in a recent policy brief.

What’s Next for Patients and Providers?

The debate over EOM accuracy underscores broader challenges in aligning healthcare data systems with evolving treatment models. As oral therapies become more common—accounting for 30% of cancer treatments, according to the American Cancer Society—correcting attribution errors will be critical. Experts warn that without action, the shift to value-based care could stall, harming both providers and patients.

“This is a call to action for policymakers, payers, and providers to invest in better data infrastructure,” said Dr. Lin. “The goal isn’t just accuracy—it’s ensuring that patients receive the care they need, regardless of how it’s delivered.”